FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Britain Courts Anthropic Amid US Defense Department Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
ATLANTA, Sept. 06, 2016 -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that the Company has granted two new hires options to purchase an aggregate of 125,000 shares of the Company's common stock with a per share exercise price of $1.33, the closing price on August 31, 2016. The stock options have a ten-year term and vests over a period of four years, with one-fourth vesting on the first anniversary of the grant date and one-fourth vesting on each of the three succeeding anniversaries. The option is subject to the terms and conditions of the Company's 2007 Omnibus Equity and Incentive Plan and the stock option agreement pursuant to which the option is granted.
The stock option was granted as an inducement material to the new employees entering into employment with Aviragen Therapeutics in accordance with NASDAQ Listing Rule 5635(c)(4).
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus upper (HRV) respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
